Avalo Therapeutics, Inc. (AVTX) News
Follow Avalo Therapeutics, Inc. (AVTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Avalo Therapeutics Reports Quarterly Results for September 30 Period
Avalo Therapeutics reported results for the quarter ended September 30; no financial figures were provided.
EQUITY | Nov 05, 2026, 07:10 PM UTC
L
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:12 PM UTC
L
Avalo Therapeutics Presents Positive Phase 2 Abdakibart Data in Hidradenitis Suppurativa
Avalo Therapeutics Presents Positive Phase 2 Abdakibart Data in Hidradenitis Suppurativa Avalo T
EQUITY | Nov 05, 2026, 04:58 PM UTC
M
Avalo Therapeutics Reports Third-Quarter 2026 Financial Results
The company also reported recent business updates, including work toward a registrational Phase 3 program for abdakibart in hidradenitis suppurativa.
EQUITY | Nov 05, 2026, 12:14 PM UTC
L
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. NASDAQ:AVTX, a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammator
NEWS | Sep 29, 2026, 08:08 PM UTC
H
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. NASDAQ:AVTX, a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammator
GEOPOLITICS | Sep 23, 2026, 11:02 AM UTC
H
AVTX - Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
AVTX - Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
GEOPOLITICS | Sep 23, 2026, 11:00 AM UTC
L
AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support
A clinical-stage biotech is advancing its potent anti-IL-1 beta antibody, abdakibart, into phase III for HS after strong phase II results and positive physician feedback. Expansion plans include a long-acting version and
EQUITY | Sep 10, 2026, 01:37 PM UTC
L
AVTX: Robust phase IIb HS data and pipeline expansion drive confidence in upcoming phase III and beyond
Strong phase IIb results for abdakibart in HS support phase III advancement, with robust efficacy, favorable safety, and high physician enthusiasm. Expansion plans include a long-acting IL-1 beta antibody and new indicat
EQUITY | Sep 10, 2026, 12:51 PM UTC
L
Avalo Therapeutics grants inducement equity awards to six new employees
Avalo Therapeutics announced inducement equity awards to six new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
Avalo Therapeutics announces inducement grants to new employees under Nasdaq Rule 5635(c)(4)
Avalo Therapeutics (AVTX) announced inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
Avalo Therapeutics to participate in upcoming investor conferences
AvaIо Therapeutics said management will participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
AVTX - Avalo Therapeutics to Participate in Upcoming Investor Conferences
AVTX - Avalo Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
AVTX - Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
AVTX - Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
AVTX Avalo Therapeutics - selling stockholders may sell up to 128,189 shares of common stock - SEC filing
AVTX Avalo Therapeutics - selling stockholders may sell up to 128,189 shares of common stock - SEC filing
REGULATION | Jul 28, 2026, 08:44 PM UTC